Prevention of eclampsia

M. A. Belfort, J. Anthony, George Saade

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Eclampsia continues to be a major cause of maternal morbidity and mortality rates, especially in underdeveloped nations. Our data indicate that eclampsia may represent the end stage of at least two very different pathophysiological pathways: one in which cerebral perfusion is low because of vasospasm and another in which cerebral perfusion is increased because of abnormal autoregulation and a failure of the normal protective mechanisms. Magnesium sulfate has been extensively used in the management and prevention of eclamptic seizures in the United States and has been recently shown to be superior to both diphenylhydantoin and diazepam. We have shown that magnesium sulfate is a potent vasorelaxant and that its action may depend on improving cerebral perfusion. Nimodipine, a calcium channel blocker with selective cerebrovascular effect, is currently under investigation in severe preeclampsia. The data show that it is as effective as magnesium sulfate in preventing eclampsia, with less maternal and fetal side effects. Magnesium sulfate and nimodipine have opposite effects on the estimated cerebral perfusion pressure as determined with the Doppler ultrasound. We speculate that the estimated cerebral perfusion pressure may be used to determine the type of cerebrovascular abnormality and the most appropriate treatment in each individual patient with preeclampsia.

Original languageEnglish (US)
Pages (from-to)65-78
Number of pages14
JournalSeminars in Perinatology
Volume23
Issue number1
StatePublished - 1999
Externally publishedYes

Fingerprint

Magnesium Sulfate
Eclampsia
Cerebrovascular Circulation
Nimodipine
Perfusion
Pre-Eclampsia
Doppler Ultrasonography
Maternal Mortality
Calcium Channel Blockers
Phenytoin
Diazepam
Vasodilator Agents
Seizures
Homeostasis
Mothers
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Belfort, M. A., Anthony, J., & Saade, G. (1999). Prevention of eclampsia. Seminars in Perinatology, 23(1), 65-78.

Prevention of eclampsia. / Belfort, M. A.; Anthony, J.; Saade, George.

In: Seminars in Perinatology, Vol. 23, No. 1, 1999, p. 65-78.

Research output: Contribution to journalArticle

Belfort, MA, Anthony, J & Saade, G 1999, 'Prevention of eclampsia', Seminars in Perinatology, vol. 23, no. 1, pp. 65-78.
Belfort MA, Anthony J, Saade G. Prevention of eclampsia. Seminars in Perinatology. 1999;23(1):65-78.
Belfort, M. A. ; Anthony, J. ; Saade, George. / Prevention of eclampsia. In: Seminars in Perinatology. 1999 ; Vol. 23, No. 1. pp. 65-78.
@article{b6fc5b4ccb43414593da49d8113540a9,
title = "Prevention of eclampsia",
abstract = "Eclampsia continues to be a major cause of maternal morbidity and mortality rates, especially in underdeveloped nations. Our data indicate that eclampsia may represent the end stage of at least two very different pathophysiological pathways: one in which cerebral perfusion is low because of vasospasm and another in which cerebral perfusion is increased because of abnormal autoregulation and a failure of the normal protective mechanisms. Magnesium sulfate has been extensively used in the management and prevention of eclamptic seizures in the United States and has been recently shown to be superior to both diphenylhydantoin and diazepam. We have shown that magnesium sulfate is a potent vasorelaxant and that its action may depend on improving cerebral perfusion. Nimodipine, a calcium channel blocker with selective cerebrovascular effect, is currently under investigation in severe preeclampsia. The data show that it is as effective as magnesium sulfate in preventing eclampsia, with less maternal and fetal side effects. Magnesium sulfate and nimodipine have opposite effects on the estimated cerebral perfusion pressure as determined with the Doppler ultrasound. We speculate that the estimated cerebral perfusion pressure may be used to determine the type of cerebrovascular abnormality and the most appropriate treatment in each individual patient with preeclampsia.",
author = "Belfort, {M. A.} and J. Anthony and George Saade",
year = "1999",
language = "English (US)",
volume = "23",
pages = "65--78",
journal = "Seminars in Perinatology",
issn = "0146-0005",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Prevention of eclampsia

AU - Belfort, M. A.

AU - Anthony, J.

AU - Saade, George

PY - 1999

Y1 - 1999

N2 - Eclampsia continues to be a major cause of maternal morbidity and mortality rates, especially in underdeveloped nations. Our data indicate that eclampsia may represent the end stage of at least two very different pathophysiological pathways: one in which cerebral perfusion is low because of vasospasm and another in which cerebral perfusion is increased because of abnormal autoregulation and a failure of the normal protective mechanisms. Magnesium sulfate has been extensively used in the management and prevention of eclamptic seizures in the United States and has been recently shown to be superior to both diphenylhydantoin and diazepam. We have shown that magnesium sulfate is a potent vasorelaxant and that its action may depend on improving cerebral perfusion. Nimodipine, a calcium channel blocker with selective cerebrovascular effect, is currently under investigation in severe preeclampsia. The data show that it is as effective as magnesium sulfate in preventing eclampsia, with less maternal and fetal side effects. Magnesium sulfate and nimodipine have opposite effects on the estimated cerebral perfusion pressure as determined with the Doppler ultrasound. We speculate that the estimated cerebral perfusion pressure may be used to determine the type of cerebrovascular abnormality and the most appropriate treatment in each individual patient with preeclampsia.

AB - Eclampsia continues to be a major cause of maternal morbidity and mortality rates, especially in underdeveloped nations. Our data indicate that eclampsia may represent the end stage of at least two very different pathophysiological pathways: one in which cerebral perfusion is low because of vasospasm and another in which cerebral perfusion is increased because of abnormal autoregulation and a failure of the normal protective mechanisms. Magnesium sulfate has been extensively used in the management and prevention of eclamptic seizures in the United States and has been recently shown to be superior to both diphenylhydantoin and diazepam. We have shown that magnesium sulfate is a potent vasorelaxant and that its action may depend on improving cerebral perfusion. Nimodipine, a calcium channel blocker with selective cerebrovascular effect, is currently under investigation in severe preeclampsia. The data show that it is as effective as magnesium sulfate in preventing eclampsia, with less maternal and fetal side effects. Magnesium sulfate and nimodipine have opposite effects on the estimated cerebral perfusion pressure as determined with the Doppler ultrasound. We speculate that the estimated cerebral perfusion pressure may be used to determine the type of cerebrovascular abnormality and the most appropriate treatment in each individual patient with preeclampsia.

UR - http://www.scopus.com/inward/record.url?scp=0033046286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033046286&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 65

EP - 78

JO - Seminars in Perinatology

JF - Seminars in Perinatology

SN - 0146-0005

IS - 1

ER -